Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity

Fig. 4

A-D AML cell lines were infected with lentivirus targeting FOXM1 for knockdown (KD#1 and KD#2) or a non-targeting control (NTC). Cells were plated into proliferation or colony-forming cell (CFC) assays after 48 h of puromycin drug selection (i.e. Day 0). Apoptosis assays were performed after four days of puromycin drug selection. A Bar chart shows mean ± SD (n = 3) cell count on Day 7 of culture in the indicated conditions. Cell counts are shown relative to Day 0. B Representative images of CFC assays. Bar charts show mean ± SD (n = 3) (C) CFC frequencies or (D) cell viability in the indicated conditions for the indicated cell lines. E-H Primary AML cells (BB104, BB108 & BB160) and normal CD34+ HSPCs from healthy donors (HD1 & HD2, apoptosis assays only) were infected with lentivirus targeting FOXM1 for knockdown (KD#1 and KD#2) or a non-targeting control (NTC). Cells were plated into proliferation or colony-forming cell (CFC) assays after 48 h of puromycin drug selection (i.e. Day 0). Apoptosis assays were performed after four days of puromycin drug selection. E Bar chart shows mean ± SD (n = 3) cell count on Day 7 of culture in the indicated conditions. Cell counts are shown relative to Day 0. F Representative images of CFC assays. Bar charts show mean ± SD (n = 3) (G) CFC frequencies or (H) cell viability in the indicated conditions for the indicated cells. * P < 0.05, ** P < 0.01, *** P < 0.001 by one-way ANOVA with Dunnett’s multiple comparison test (A-G) or unpaired t-test (H). BB numbers indicate Biobank identifier

Back to article page